Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Completed · Phase 1

Conditions studied: Cancer

In brief

LVGN7409 is a humanized monoclonal antibody that specifically binds to CD40, and acts as an agonist against CD40. This first in human study of LVGN7409 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN7409, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody and/or CD137 agonist in the treatment of advanced or metastatic malignancy.

Key facts

Study ID

NCT04635995

Run by

Lyvgen Biopharma Holdings Limited

People needed

66

Starts

2020-12-11

Expected to finish

2025-12-31

Last updated by the study team

2026-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females aged ≥ 18 years.
• Ability to understand and willingness to sign a written informed consent document.
• Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.
• Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.
• Adequate bone marrow, liver, and renal functions
• Men and women of childbearing potential must agree to take highly effective contraceptive methods.
• Patients should recover from all reversible AEs of previous anticancer therapies to baseline.
• Patients infected with the HIV virus will be eligible if the disease is under control of effective therapy.

You may not qualify if…

• Prior therapy with anti-CD40 therapy.
• Receipt of systemic anticancer therapy or radiotherapy within certain period of time.
• Prior exposure to immune-therapeutics experienced Grade ≥ 3 drug-related toxicity, or a toxicity requiring discontinuation.
• Received a live-virus vaccine within 30 days of the first dose of study drug.
• Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.
• History of Grade ≥ 3 immune-related AEs (irAEs).
• Prolonged QT syndrome, or clinically significant cardiac condition.
• Receiving an immunologically based treatment for any reason.
• History or current active or chronic autoimmune disease.
• Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage.
• Female patients who are pregnant or breastfeeding.
• History of hemorrhagic or ischemic stroke within the last 6 months.
• Previously received an allogeneic tissue/organ transplant, stem cell or bone marrow transplant or solid organ transplant.

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.